ARTICLE | Finance
New Dyrction
Xoma spinout Symplmed to use new platform to market blood pressure meds
July 15, 2013 7:00 AM UTC
Symplmed Pharmaceuticals LLC found an individual investor who has bought into the company's plan of introducing a disruptive sales strategy that incentivizes doctors and patients to use its blood pressure therapies.
The newco, which spun out of Xoma Corp. (NASDAQ:XOMA) this month, will start rolling out its Dyrct Axess marketing platform this quarter using Aceon perindopril as its test case...